Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

MorphoSys to Host Conference Call on Bio-Rad's planned Acquisition of MorphoSys's Research and Diagnostic Antibody Business AbD Serotec


Print article Print article
© Marketwire 2012
2012-12-17 07:42:07 -

MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 12/17/12 -- MorphoSys AG /
MorphoSys to Host Conference Call on Bio-Rad's planned Acquisition of
MorphoSys's Research and Diagnostic Antibody Business AbD Serotec.



Processed and transmitted by Thomson Reuters ONE.



The issuer is solely responsible for the content of this announcement.



Today at 2:00 p.m. CET (1:00 p.m. GMT, 8:00 a.m. EST), the Management Board
of
MorphoSys AG will host a public conference call and webcast to present
information on Bio-Rad's planned acquisition of MorphoSys's research and
diagnostic antibody business AbD Serotec.







Dial-in numbers for the Conference Call (listen-only):



Germany: +49 (0) 89 2444 32975



For U.K. residents: +44 (0) 20 3003 2666



For U.S. residents: +1 202 204 1514





MorphoSys offers participants the opportunity to follow the presentation
through
a simultaneous slide presentation online at www.morphosys.com : www.morphosys.com .



An audio replay and manuscripts of the conference will be
available on
www.morphosys.com/conference-calls : www.morphosys.com/conference-calls in due course.





About MorphoSys:



MorphoSys developed HuCAL, the most successful antibody library technology
in
the pharmaceutical industry. By successfully applying this and other
patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment
of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates
about MorphoSys, visit www.morphosys.com : www.morphosys.com




HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®,
Ylanthia® and 100 billion high potentials® are registered
trademarks of
MorphoSys AG.



Slonomics® is a registered trademark of Sloning BioTechnology
GmbH, a
subsidiary of MorphoSys AG.




This communication contains certain forward-looking statements
concerning the
MorphoSys group of companies. The forward-looking statements contained
herein
represent the judgment of MorphoSys as of the date of this release and
involve
risks and uncertainties. Should actual conditions differ from the
Company's
assumptions, actual results and actions may differ from those
anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as
far as the wording of the relevant press release is concerned.



Conference Call Alert (PDF):



hugin.info/130295/R/1665497/540379.pdf : hugin.info/130295/R/1665497/540379.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:



(i) the releases contained herein are protected by copyright and
other applicable laws; and



(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.



Source: MorphoSys AG via Thomson Reuters ONE



[HUG#1665497]




For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Email Contact : www2.marketwire.com/mw/emailprcntct?id=82B8D0675E704E12



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com